You are here

AI-Enabled Test for Kidney Disease Gets Breakthrough Device Designation

FDA Gives Priority Regulatory Review of Diagnostic for Fast-Progressing Kidney Disease

Renalytix AI plc has received an FDA Breakthrough Device Designation for KidneyIntelXTM, its main diagnostic test for kidney disease.

The device is designed to diagnose and improve clinical management of patients with type-2 diabetes with fast-progressing kidney disease. Using machine-learning algorithms, KidneyIntelX will assess the combination of predictive blood-based biomarkers, including sTNFR1, sTNFR2 and KIM1, with electronic health record information, to identify progressive kidney disease.

Globally, kidney disease is recognized as a public health epidemic affecting more than 850 million people, making its early detection and intervention crucial. The annual cost of chronic and end-stage kidney disease to the U.S. health care system is estimated to be $114 billion. Each day, 13 patients die in the U.S. while waiting for a kidney transplant.

Source: Renalytix AI plc, May 2, 2019

Recent Headlines

Scenesse is new treatment for people with rare, painful light sensitivity disease
Humira, Rituxan top list of drugs that added $5.1 billion to nation's health care bill
Lower court rulings cleared the way for generic versions of the MS drug
Maryland man wins lawsuit that alleges that the company's antipsychotic caused his gynecomastia
Antidepressants, ADHD meds are also used to self-poison
Study lists steps that could save close to $300 billion a year
While many victims used THC, the cause remains elusive
Descovy joins Truvada, another Gilead product, in the HIV prophylaxis market
Data show PTC Therapeutics drug preserves lung function